Conditions: Multiple Sclerosis
Keywords: Multiple Sclerosis, demyelinating autoimmune diseases, interleukin-17, monoclonal human antibody
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 39
Healthy volunteers: no

Brief summary:
The study will assess the long-term safety and tolerability of AIN457 in patients with relapsing-remitting multiple sclerosis (RRMS). In addition the long-term pattern of maintenance of efficacy and health related quality of life will be explored.

Detailed description:

Arms:
arm 1: (10mg/kg i.v.). AIN 457 core study /AIN 457 Extension arm 2: (10mg/kg i.v.). AIN 457 placebo core study /AIN 457 Extension

Interventions: intervention 1: AIN457 intervention 2: AIN457
Intervention descriptions: intervention 1: (10mg/kg i.v.). intervention 2: (10mg/kg i.v.).

Protocol document: